{"product_id":"mirumpharma-business-model-canvas","title":"Mirum Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a concise Business Model Canvas to scale value, partnerships, and monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Mirum’s strategic blueprint with our concise Business Model Canvas — three to five sentences that reveal how Mirum creates value, scales through partnerships, and monetizes customer segments; perfect for entrepreneurs, investors, and consultants seeking actionable insights. Purchase the full, editable Canvas to access all nine blocks, financial implications, and a ready-to-use template for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and CDMOs for trials and manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCROs and CDMOs shorten time-to-market and lower capital intensity by providing specialized trial operations, CMC development, scale-up, and GMP production. They de-risk tech transfer and assure supply continuity for rare disease populations, which affect an estimated 6–8% of the global population (WHO). Structured QP release and robust quality systems enable synchronized global filings across major regulators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic hepatology centers and KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeading liver disease centers enable patient identification, protocol refinement, and rapid enrollment, shortening multicenter trial timelines by up to 30%. KOLs validate endpoints and drive guideline inclusion, which correlates with higher adoption post-approval. Co-authored publications elevate clinical credibility and long-term collaborations feed pipeline insights into cholestatic pathophysiology amid a global chronic liver disease burden of ~2 million deaths\/year (WHO 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy groups and registries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups accelerate disease awareness and trial recruitment in small populations and connect study teams to patients across more than 7,000 rare diseases affecting roughly 300 million people worldwide.\u003c\/p\u003e\n\u003cp\u003eRegistries document natural history, provide external comparator benchmarks and generate real-world evidence increasingly used in regulatory filings following FDA\/EMA RWE guidance.\u003c\/p\u003e\n\u003cp\u003eThey also support patient education, adherence initiatives and co-created access programs that improve equity of care and reduce barriers to treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, HTA bodies, and specialty pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly engagement with payers and HTA bodies shapes value dossiers and outcomes contracts, and HTA alignment in 2024 clarified evidence thresholds for many rare indications; specialty pharmacies ensure appropriate dispensing, cold-chain integrity and patient support, while data-sharing agreements enable persistence and outcomes monitoring—specialty drugs now account for ~50% of US drug spend despite \u0026lt;3% of prescriptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly HTA engagement\u003c\/li\u003e\n\u003cli\u003eOutcomes-based contracts\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy cold-chain \u0026amp; support\u003c\/li\u003e\n\u003cli\u003eData-sharing for persistence\/outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and biomarker laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with diagnostic and biomarker laboratories enable Mirum to screen eligible patients via bile acid, genetic and biomarker panels, while companion diagnostics refine targeting and quantify treatment response; lab integration reduces diagnosis-to-therapy time. Shared datasets from trials and real-world cohorts (2024 IVD market ~100B USD) strengthen mechanistic validation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScreening: bile acid\/genetic\/biomarker panels\u003c\/li\u003e\n\u003cli\u003eCompanion diagnostics: target \u0026amp; response\u003c\/li\u003e\n\u003cli\u003eFaster diagnosis-to-therapy\u003c\/li\u003e\n\u003cli\u003eShared datasets: mechanistic validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners cut time-to-market \u003cstrong\u003e30%\u003c\/strong\u003e, connect \u003cstrong\u003e300M\u003c\/strong\u003e patients, IVD ≈ \u003cstrong\u003e100B USD\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCROs\/CDMOs cut time-to-market up to 30% and ensure GMP supply; liver centers\/KOLs shorten enrollment ~30% and validate endpoints amid ~2M annual liver deaths (WHO 2024); patient groups\/registries connect ~300M rare-disease patients and enable RWE; payers\/HTA\/specialty pharmacies shape access as specialty drugs = ~50% US drug spend (2024), diagnostics (IVD) market ≈100B USD (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/CDMOs\u003c\/td\u003e\n\u003ctd\u003eTime-to-market, GMP supply\u003c\/td\u003e\n\u003ctd\u003eUp to −30% timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver centers\/KOLs\u003c\/td\u003e\n\u003ctd\u003eEnrollment, endpoints\u003c\/td\u003e\n\u003ctd\u003e~30% faster; 2M liver deaths\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\/registries\u003c\/td\u003e\n\u003ctd\u003eRWE, recruitment\u003c\/td\u003e\n\u003ctd\u003e~300M rare-disease patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/HTA\/Pharmacies\u003c\/td\u003e\n\u003ctd\u003eAccess, outcomes\u003c\/td\u003e\n\u003ctd\u003eSpecialty = ~50% US spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eScreening, companion Dx\u003c\/td\u003e\n\u003ctd\u003eIVD market ≈100B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Mirum Business Model Canvas mapping customer segments, value propositions, channels and revenue streams across the 9 classic BMC blocks, with narrative, competitive advantages and linked SWOT analysis for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMirum Business Model Canvas eliminates the pain of formatting and scattered notes by delivering an editable one-page snapshot of your strategy. It saves hours, improves team alignment, and makes comparing or iterating business models fast and effortless.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development in cholestatic liver diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execution of Phase 2–4 trials span pediatric and adult cohorts for maralixibat, leveraging the FDA approval in 2021 for Alagille syndrome to accelerate registrational and lifecycle studies. Endpoint selection prioritizes clinician- and patient-reported pruritus scales, serum bile acid reductions and validated quality-of-life instruments. Global site activation and rare-disease retention tactics focus on specialist centers and patient advocacy networks, with post-marketing studies planned to support expanded indications and label claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngage FDA, EMA and other agencies to secure orphan, fast track or breakthrough designations, leveraging FDA goal review times of 10 months (standard) and 6 months (priority) and EMA centralized review of ~210 days. Prepare INDs, NDAs\/MAAs and formal responses to agency queries. Pursue label expansions via supplemental filings and PIPs. Maintain RMPs and continuous pharmacovigilance to sustain compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing scale-up and supply chain assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTech transfer and process validation scale Mirum from clinical to dual-site GMP production to protect supply for orphan populations (US orphan threshold \u0026lt;200,000; WHO estimates 300 million people live with rare diseases globally). Forecasting models account for small, geographically dispersed cohorts and enable targeted batch runs. Cold-chain logistics (2–8°C or ultra-cold as required) plus serialization per EU\/FDA track-and-trace rules ensure traceability. Continuous quality monitoring and real-time analytics minimize interruptions and support regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs and scientific education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical affairs drives MSL engagement, congress presentations and peer-reviewed publications to build credibility for Mirum (NASDAQ: MIRM), developing evidence-based HCP and payer materials and convening advisory boards to capture treatment insights and unmet needs. Real-world data generation supports uptake and reimbursement decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMSL-led HCP engagement\u003c\/li\u003e\n\u003cli\u003eCongress abstracts \u0026amp; publications\u003c\/li\u003e\n\u003cli\u003eEvidence materials for HCPs\/payers\u003c\/li\u003e\n\u003cli\u003eAdvisory boards capturing unmet needs\u003c\/li\u003e\n\u003cli\u003eRWE generation for uptake \u0026amp; reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and patient support operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarket access and patient support operations build value dossiers and execute ICER\/HTA submissions and pricing strategy development; in 2024 firms prioritized outcomes contracting to align payment with real-world value. Prior authorization support, copay assistance and nurse navigation reduce access friction, while adherence programs improve persistence in chronic conditions and lower total cost of care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue dossier \u0026amp; HTA alignment\u003c\/li\u003e\n\u003cli\u003ePricing strategy \u0026amp; outcomes contracting\u003c\/li\u003e\n\u003cli\u003ePrior auth, copay, nurse navigation\u003c\/li\u003e\n\u003cli\u003eAdherence programs → higher persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDesign\/execution of Phase 2–4 trials across cohorts; accelerate registrational filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/execution of Phase 2–4 trials across pediatric\/adult cohorts; endpoints: clinician\/patient pruritus scales, serum bile acids, QoL; leverage 2021 FDA approval for registrational acceleration. Regulatory: IND\/NDA\/MAA filings, orphan\/priority designations (FDA review 6–10 months; EMA ~210 days). Manufacturing: dual-site GMP, cold-chain, serialization; supply planning for US orphan \u0026lt;200,000. Market access: HTA dossiers, outcomes contracting, prior auth and patient support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKPI\u003c\/th\u003e\n\u003cth\u003e2024 benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003eSubjects\/site\u003c\/td\u003e\n\u003ctd\u003e5–15 rare-disease pts\/site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eReview time\u003c\/td\u003e\n\u003ctd\u003eFDA 6–10 months; EMA ~210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eBatch runs\/year\u003c\/td\u003e\n\u003ctd\u003e4–12 targeted runs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket access\u003c\/td\u003e\n\u003ctd\u003eOutcomes contracts\u003c\/td\u003e\n\u003ctd\u003eAdopted by top payers in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Mirum Business Model Canvas you'll receive—not a mockup. After purchase you'll download this exact file, complete and editable. It comes formatted for immediate use in Word and Excel, with all sections included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162287518073,"sku":"mirumpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/mirumpharma-business-model-canvas.png?v=1762698444","url":"https:\/\/portersfiveforce.com\/products\/mirumpharma-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}